Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.

IF 25.4 1区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

MMWR. Morbidity and mortality weekly report Pub Date : 2024-10-10 DOI:10.15585/mmwr.mm7340a3

Crystal M Gigante, Jade Takakuwa, Daisy McGrath, Chantal Kling, Todd G Smith, Mengfei Peng, Kimberly Wilkins, Jacob M Garrigues, Taylor Holly, Hannah Barbian, Alyse Kittner, Danielle Haydel, Emma Ortega, Gillian Richardson, Julie Hand, Jill K Hacker, Alex Espinosa, Monica Haw, Chantha Kath, Meilan Bielby, Kirstin Short, Kimberly Johnson, Nelson De La Cruz, Whitni Davidson, Christine Hughes, Nicole M Green, Nicolle Baird, Agam K Rao, Christina L Hutson

{"title":"Notes from the Field: Mpox Cluster Caused by Tecovirimat-Resistant Monkeypox Virus - Five States, October 2023-February 2024.","authors":"Crystal M Gigante, Jade Takakuwa, Daisy McGrath, Chantal Kling, Todd G Smith, Mengfei Peng, Kimberly Wilkins, Jacob M Garrigues, Taylor Holly, Hannah Barbian, Alyse Kittner, Danielle Haydel, Emma Ortega, Gillian Richardson, Julie Hand, Jill K Hacker, Alex Espinosa, Monica Haw, Chantha Kath, Meilan Bielby, Kirstin Short, Kimberly Johnson, Nelson De La Cruz, Whitni Davidson, Christine Hughes, Nicole M Green, Nicolle Baird, Agam K Rao, Christina L Hutson","doi":"10.15585/mmwr.mm7340a3","DOIUrl":null,"url":null,"abstract":"The antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat† (1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public databases. MPXV F13 mutations associated with resistance have been reported since 2022, typically among severely immunocompromised mpox patients who required prolonged courses of tecovirimat (3-5). A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.","PeriodicalId":18637,"journal":{"name":"MMWR. Morbidity and mortality weekly report","volume":"73 40","pages":"903-905"},"PeriodicalIF":25.4000,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466377/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MMWR. Morbidity and mortality weekly report","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7340a3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

The antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat^† (1,2). CDC and public health partners have conducted genetic surveillance of monkeypox virus (MPXV) for F13 mutations through sequencing and monitoring of public databases. MPXV F13 mutations associated with resistance have been reported since 2022, typically among severely immunocompromised mpox patients who required prolonged courses of tecovirimat (3-5). A majority of patients with infections caused by MPXV with resistant mutations had a history of tecovirimat treatment; however, spread of tecovirimat-resistant MPXV was reported in California during late 2022 to early 2023 among persons with no previous tecovirimat treatment (3). This report describes a second, unrelated cluster of tecovirimat-resistant MPXV among 18 persons with no previous history of tecovirimat treatment in multiple states.

查看原文本刊更多论文

现场笔记：由耐 Tecovirimat 猴痘病毒引起的猴痘集群 - 五个州，2023 年 10 月至 2024 年 2 月。

自 2022 年全球疫情爆发以来，抗病毒药物替考韦利马特（tecovirimat*）一直被广泛用于治疗美国的麻腮风病例。在治疗过程中，水痘病毒蛋白靶点（F13 或 VP37）发生的突变可导致对替考韦利马特产生耐药性（1,2）。疾病预防控制中心和公共卫生合作伙伴通过测序和监测公共数据库，对猴痘病毒 (MPXV) 的 F13 突变进行了基因监测。自 2022 年以来，与耐药性相关的 MPXV F13 变异已有报道，通常发生在免疫力严重低下的猴痘患者中，他们需要长期服用替考韦瑞（tecovirimat）（3-5）。大多数由具有耐药性突变的 MPXV 引起的感染患者都有过替考韦瑞马特治疗史；然而，2022 年末至 2023 年初，加利福尼亚州报道了耐替考韦瑞马特 MPXV 在既往未接受过替考韦瑞马特治疗的人群中传播的情况（3）。本报告描述了在多个州的 18 名既往未接受过替考病毒治疗的人中出现的第二个不相关的耐替考病毒 MPXV 群体。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

MMWR. Morbidity and mortality weekly report PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH -

CiteScore

65.40

自引率

0.90%

发文量

309

期刊介绍： The Morbidity and Mortality Weekly Report (MMWR ) series is prepared by the Centers for Disease Control and Prevention (CDC). Often called “the voice of CDC,” the MMWR series is the agency’s primary vehicle for scientific publication of timely, reliable, authoritative, accurate, objective, and useful public health information and recommendations. MMWR readership predominantly consists of physicians, nurses, public health practitioners, epidemiologists and other scientists, researchers, educators, and laboratorians.